• “The companies on the right, that you think are the ones running this show [Pfzer, Moderna, Johnson & Johnson, Merck Ridgeback, Gilead Sciences], are in fact a front
    [for the companies on the left, Anser, Fors-Marsh, Palantir, Publicis Sapient].
    “The companies on the right, that you think are the ones running this show [Pfzer, Moderna, Johnson & Johnson, Merck Ridgeback, Gilead Sciences], are in fact a front [for the companies on the left, Anser, Fors-Marsh, Palantir, Publicis Sapient].
    0 Comments 0 Shares 879 Views
  • #Molnupiravir invented at #Emory University before #COVID19 pandemic, shown promise against all sort of viruses - and #Trump administration is extremely interested to invest in the research of it.

    Trump HHS official #RobertKadlec urged #BARDA in Nov 2019 to invest millions into the "miracle cure". However #RickBright, the former BARDA director turn "#whistleblower" refused, claiming that the request is based on political connections and cronyism.

    Molnupiravir, licensed by Emory to #Ridgeback, was unable to get funding in April 2020 (at the height of the pandemic) is taken up by #Merck and privately funded.

    In the end, Molnupiravir is proven to be the ONLY pill administered #COVID19 drug that is showing tremendously promise in it's Phase 3 trial (reduce serious covid by at least 50%), and is currently seeking #FDA emergency-use authorization (#EUA) - which would likely herald the end of the #pandemic and return world back to normalcy.

    https://youtu.be/y05oC0eZ100
    #Molnupiravir invented at #Emory University before #COVID19 pandemic, shown promise against all sort of viruses - and #Trump administration is extremely interested to invest in the research of it. Trump HHS official #RobertKadlec urged #BARDA in Nov 2019 to invest millions into the "miracle cure". However #RickBright, the former BARDA director turn "#whistleblower" refused, claiming that the request is based on political connections and cronyism. Molnupiravir, licensed by Emory to #Ridgeback, was unable to get funding in April 2020 (at the height of the pandemic) is taken up by #Merck and privately funded. In the end, Molnupiravir is proven to be the ONLY pill administered #COVID19 drug that is showing tremendously promise in it's Phase 3 trial (reduce serious covid by at least 50%), and is currently seeking #FDA emergency-use authorization (#EUA) - which would likely herald the end of the #pandemic and return world back to normalcy. https://youtu.be/y05oC0eZ100
    Like
    1
    0 Comments 0 Shares 3K Views
  • First of all, it's not the 1st, it is an unkown, probably not the best or safest or certainly not the cheapest, and 2nd of all anything hyped and rushed through approval like this Molnupiravir by the Deep State 'Machine That IS', i'd say could be as bad as taking the vaccines. :

    --- from newsweek; Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19.

    If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, (???)could be the first (??? WHAT ABOUT HCQ , Zinc Compounds and Ivermectin) oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide."

    The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with mild or moderate cases of COVID-19. https://www.newsweek.com/what-molnupiravir-first-oral-covid-treatment-could-issued-years-end-1634656
    First of all, it's not the 1st, it is an unkown, probably not the best or safest or certainly not the cheapest, and 2nd of all anything hyped and rushed through approval like this Molnupiravir by the Deep State 'Machine That IS', i'd say could be as bad as taking the vaccines. : --- from newsweek; Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19. If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, (???)could be the first (??? WHAT ABOUT HCQ , Zinc Compounds and Ivermectin) oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide." The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with mild or moderate cases of COVID-19. https://www.newsweek.com/what-molnupiravir-first-oral-covid-treatment-could-issued-years-end-1634656
    WWW.NEWSWEEK.COM
    What is Molnupiravir? First oral COVID treatment could be issued by year's end
    The companies said that an interim analysis found molnupiravir reduced the risk of hospitalization or death by approximately 50 percent..
    0 Comments 2 Shares 782 Views
  • Remember when Trump pushed for lower drug prices and then Biden halted his executive orders when he got in office?

    Yep. Those days are over, friends.

    https://theintercept.com/2021/10/05/covid-pill-drug-pricing-merck-ridgeback/
    Remember when Trump pushed for lower drug prices and then Biden halted his executive orders when he got in office? Yep. Those days are over, friends. https://theintercept.com/2021/10/05/covid-pill-drug-pricing-merck-ridgeback/
    THEINTERCEPT.COM
    Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to Make
    The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense.
    Like
    Wow
    2
    0 Comments 1 Shares 752 Views
Sponsored

We are 100% funded for October.

Thanks to everyone who helped out. 🥰

Xephula monthly operating expenses for 2024 - Server: $143/month - Backup Software: $6/month - Object Storage: $6/month - SMTP Service: $10/month - Stripe Processing Fees: ~$10/month - Total: $175/month

Xephula Funding Meter

Please Donate Here